BTIG Research Initiates Coverage on DexCom to Buy

BTIG Research Initiates Coverage on DexCom(NASDAQ:DXCM). The shares have been rated Buy. The rating by BTIG Research was issued on Apr 14, 2016.

In a different note, On Feb 24, 2016, Jefferies said it Maintains its rating on DexCom. In the research note, the firm Lowers the price-target to $100.00 per share. The shares have been rated ‘Buy’ by the firm. On Feb 24, 2016, JP Morgan said it Maintains its rating on DexCom. In the research note, the firm Lowers the price-target to $120.00 per share. The shares have been rated ‘Overweight’ by the firm. On Feb 8, 2016, Baird said it Downgrades its rating on DexCom. In the research note, the firm Lowers the price-target to $100.00 per share. The shares have been rated ‘Neutral’ by the firm.

DexCom (DXCM) made into the market gainers list on Mondays trading session with the shares advancing 1.27% or 0.85 points. Due to strong positive momentum, the stock ended at $67.66, which is also near the day’s high of $68.035. The stock began the session at $66.38 and the volume stood at 4,29,620 shares. The 52-week high of the shares is $103.29 and the 52 week low is $47.92. The company has a current market capitalization of $5,531 M and it has 8,17,40,827 shares in outstanding.

DexCom(DXCM) last announced its earnings results on Feb 23, 2016 for Fiscal Year 2015 and Q4.Company reported revenue of $130.80M. Analysts had an estimated revenue of $123.74M. Earnings per share were $0.02. Analysts had estimated an EPS of $0.01.

Several Insider Transactions has been reported to the SEC. On Apr 12, 2016, Terrance H Gregg (Executive Chairman) sold 2,169 shares at $68.00 per share price.Also, On Apr 5, 2016, Steven Robert Pacelli (EVP, Strategy & Corp. Dev.) sold 20,600 shares at $70.62 per share price.On Apr 5, 2016, Jorge A Valdes (CTO) sold 20,000 shares at $70.08 per share price, according to the Form-4 filing with the securities and exchange commission.

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Leave a Reply

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.